- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Dr. Reddy's Laboratories Limited — Board Meeting, 21-01-2026: Outcome of Board Meeting
21-01-2026 | 05:03 pm
21-01-2026 | 05:03 pm
Dr. Reddy's board approved Q3FY26 consolidated financials: Revenue ₹8,726.8 Cr (+4.4% YoY), Net Profit ₹1,209.8 Cr (-14% YoY). Key updates include an Immutep oncology drug deal, new vaccine launch in India, and EU/UK approval for a biosimilar, but also US FDA CRLs for two biosimilars.
No comments yet. Be the first to comment!